Presystemic and systemic glucuronidation of propranolol. 1979

T Walle, and T C Fagan, and E C Conradi, and U K Walle, and T E Gaffney

The relative importance of presystemic and systemic glucuronidation of propranolol was examined in normal subjects given single oral and intravenous doses of propranolol. The areas under the plasma concentration--time curves (AUCs) of propranolol glucuronide (PG), 41 +/- 15 ng . hr/ml, and propranolol, 48 +/- 15 ng . hr/ml, were of the same order after the intravenous dose (0.05 mg/kg). After oral doses of 20 and 80 mg, the AUCs of PG were 302 +/- 105 and 1,398 +/- 409 ng . hr/ml; these were 7 times the AUCs of propranolol, 44 +/- 15 and 220 +/- 38 ng . hr/ml. The time lapse to peak concentration, 1.5 to 3.0 hr, and the plasma half-life, 3.2 to 3.7 hr, were the same for PG and propranolol. These results demonstrate glucuronidation as an important determinant of propranolol bioavailability.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D005965 Glucuronates Derivatives of GLUCURONIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that include the 6-carboxy glucose structure. Glucosiduronates,Glucuronic Acids,Acids, Glucuronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

T Walle, and T C Fagan, and E C Conradi, and U K Walle, and T E Gaffney
June 1982, Journal of pharmaceutical sciences,
T Walle, and T C Fagan, and E C Conradi, and U K Walle, and T E Gaffney
June 2002, Drug metabolism and disposition: the biological fate of chemicals,
T Walle, and T C Fagan, and E C Conradi, and U K Walle, and T E Gaffney
February 1998, Drug metabolism and disposition: the biological fate of chemicals,
T Walle, and T C Fagan, and E C Conradi, and U K Walle, and T E Gaffney
August 1991, The Journal of pharmacology and experimental therapeutics,
T Walle, and T C Fagan, and E C Conradi, and U K Walle, and T E Gaffney
January 1985, Drug metabolism and disposition: the biological fate of chemicals,
T Walle, and T C Fagan, and E C Conradi, and U K Walle, and T E Gaffney
January 1983, Biopharmaceutics & drug disposition,
T Walle, and T C Fagan, and E C Conradi, and U K Walle, and T E Gaffney
November 1985, The Journal of pharmacy and pharmacology,
T Walle, and T C Fagan, and E C Conradi, and U K Walle, and T E Gaffney
May 2010, Chirality,
T Walle, and T C Fagan, and E C Conradi, and U K Walle, and T E Gaffney
February 1986, Xenobiotica; the fate of foreign compounds in biological systems,
T Walle, and T C Fagan, and E C Conradi, and U K Walle, and T E Gaffney
May 1984, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!